Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors

Combination chemoimmunotherapy (CIT) consisting of anti-CD20 has improved the progression-free survival (PFS) and overall survival (OS) of patients with chronic lymphocytic leukaemia (CLL). We performed a comprehensive synthesis of prognostic factors in patients with CLL on combined CIT with anti-CD...

Descripción completa

Detalles Bibliográficos
Autores principales: Mkhwanazi, Zekhethelo A., Nyambuya, Tawanda M., Mfusi, Snenhlanhla A., Nkambule, Bongani B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701011/
https://www.ncbi.nlm.nih.gov/pubmed/36434612
http://dx.doi.org/10.1186/s12885-022-10223-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701011/
https://www.ncbi.nlm.nih.gov/pubmed/36434612
http://dx.doi.org/10.1186/s12885-022-10223-0

Ejemplares similares